Table 3.
Multivariate odds ratiosa of high-grade and aggressive prostate cancer by ADIPOQ sequence variants using the dominant model in the Physicians Health Study, 1982-2009.
| High-grade/Poorly differentiated PCa (Gleason 4+3 & 8-10, n=276) | Aggressive PCa (T3, N1, M1 or boney metastases during follow-up, n=252) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SNP | N b (cases) | OR a | 95% CI | p-value | N b (cases) | OR a | 95% CI | p-value | ||||
| 1 | rs266729 | CC | 138 | 1.00 | reference | -- | 117 | 1.00 | reference | -- | ||
| CG/GG | 113 | 1.09 | 0.83 | 1.44 | 0.53 | 104 | 1.17 | 0.87 | 1.57 | 0.31 | ||
| 2 | rs182052 | GG | 125 | 1.00 | reference | -- | 109 | 1.00 | reference | -- | ||
| AG/AA | 136 | 0.94 | 0.72 | 1.23 | 0.66 | 128 | 1.00 | 0.75 | 1.34 | 0.98 | ||
| 3 | rs168681205 | GG | 234 | 1.00 | reference | -- | 209 | 1.00 | reference | -- | ||
| AG/AA | 35 | 1.08 | 0.72 | 1.61 | 0.71 | 38 | 1.26 | 0.84 | 1.88 | 0.26 | ||
| 4 | rs168681209 | CC | 220 | 1.00 | reference | -- | 205 | 1.00 | reference | -- | ||
| AC/AA | 46 | 0.85 | 0.6 | 1.21 | 0.36 | 38 | 0.81 | 0.55 | 1.19 | 0.27 | ||
| 5 | rs822391 | TT | 180 | 1.00 | reference | -- | 166 | 1.00 | reference | -- | ||
| CT/CC | 86 | 0.84 | 0.64 | 1.12 | 0.24 | 76 | 0.79 | 0.59 | 1.07 | 0.13 | ||
| 6 | rs12495941 | GG | 112 | 1.00 | reference | -- | 98 | 1.00 | reference | -- | ||
| GT/TT | 139 | 0.93 | 0.7 | 1.22 | 0.58 | 126 | 0.94 | 0.70 | 1.26 | 0.66 | ||
| 7 | rs17366568 | GG | 202 | 1.00 | reference | -- | 176 | 1.00 | reference | -- | ||
| AG/AA | 54 | 0.9 | 0.65 | 1.26 | 0.55 | 51 | 1.00 | 0.70 | 1.42 | 0.99 | ||
| 8 | rs3821799 | CC | 86 | 1.00 | reference | -- | 79 | 1.00 | reference | -- | ||
| CT/TT | 180 | 0.8 | 0.6 | 1.07 | 0.13 | 164 | 0.83 | 0.61 | 1.12 | 0.22 | ||
| 9 | rs3774261 | GG | 103 | 1.00 | reference | -- | 97 | 1.00 | reference | -- | ||
| AG/AA | 166 | 0.89 | 0.67 | 1.17 | 0.39 | 147 | 0.88 | 0.66 | 1.18 | 0.39 | ||
| 10 | rs17366743 | TT | 245 | 1.00 | reference | -- | 215 | 1.00 | reference | -- | ||
| CT/CC | 12 | 0.76 | 0.4 | 1.43 | 0.39 | 16 | 1.23 | 0.69 | 2.19 | 0.49 | ||
| 11 | rs2082940 | CC | 212 | 1.00 | reference | -- | 198 | 1.00 | reference | -- | ||
| CT/TT | 52 | 0.78 | 0.56 | 1.08 | 0.13 | 46 | 0.76 | 0.53 | 1.08 | 0.12 | ||
| 12 | rs7639352 | CC | 143 | 1.00 | reference | -- | 135 | 1.00 | reference | -- | ||
| CT/TT | 118 | 0.98 | 0.74 | 1.29 | 0.87 | 100 | 0.96 | 0.72 | 1.28 | 0.77 | ||
a
among Caucasians only, adjusted for age at randomization (yrs, continuous), cigarette smoking status (never, current, past) and time between blood draw & event date (yrs, continuous))
b
may not add up to total number of cases (n=276 & n=252) if genotype is missing for some participants.